Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for enGene Therapeutics Inc (ENGN : NSDQ)

• Company Description    enGene Holdings Inc. is a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues. enGene Holdings Inc., formerly known as Forbion European Acquisition Corp., is based in MONTREAL. Number of Employees: 82

• Price / Volume Information    Yesterday's Closing Price: $1.64 Daily Weekly Monthly 20 Day Moving Average: 3,775,385 shares Shares Outstanding: 66.99 (millions) Market Capitalization: $109.86 (millions) Beta: -0.02 52 Week High: $12.25 52 Week Low: $1.40 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -79.85% -80.84% 12 Week -83.65% -84.88% Year To Date -81.84% -82.39%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4868 RUE LEVY SUITE 220 - SAINT-LAURENT,A8 H4R 2P1 CAN ph: 514-332-4888 fax: - investors@engene.com https://engene.com

• General Corporate Information    Officers Ronald H. W. Cooper - Chief Executive Officer Ryan Daws - Chief Financial Officer Jasper Bos - Director Gerald Brunk - Director Dr. Richard Glickman - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 29286X101 SIC: 2836 Fiscal Year Fiscal Year End: October Last Reported Quarter: 01/01/26 Next Expected EPS Date: 06/11/26 Share - Related Items Shares Outstanding: 66.99 Most Recent Split Date: (:1) Beta: -0.02 Market Capitalization: $109.86 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.54 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.06 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 06/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.39 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 8.33% vs. Previous Quarter: 39.73% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 04/30/26 - - 01/31/26 - -55.83 10/31/25 - -55.49 ROA 04/30/26 - - 01/31/26 - -45.74 10/31/25 - -46.02 Current Ratio 04/30/26 - - 01/31/26 - 11.75 10/31/25 - 6.30 Quick Ratio 04/30/26 - - 01/31/26 - 11.75 10/31/25 - 6.30 Operating Margin 04/30/26 - - 01/31/26 - - 10/31/25 - - Net Margin 04/30/26 - - 01/31/26 - - 10/31/25 - - Pre-Tax Margin 04/30/26 - - 01/31/26 - - 10/31/25 - - Book Value 04/30/26 - - 01/31/26 - 4.20 10/31/25 - 2.60 Inventory Turnover 04/30/26 - - 01/31/26 - - 10/31/25 - - Debt-to-Equity 04/30/26 - - 01/31/26 - 0.09 10/31/25 - 0.09 Debt-to-Capital 04/30/26 - - 01/31/26 - 8.08 10/31/25 - 8.37

Powered by Zacks Investment Research ©